Revolutions Medical (RMCP) 10-Q 29 Aug 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 29, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Revolutions Medical CORP	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	150,426,703
Amendment Flag	'false	'
Entity Central Index Key	'0001041009	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

Balance_Sheets_Unaudited

Balance Sheets (Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash and cash equivalents	$16,888	$932
Inventories	279,813	278,564
Prepaid expenses and other current assets	6,318	2,932
Total current assets	303,019	282,428
Property and equipment, net	228,056	270,189
Intangibles	139,234	133,517
Total assets	670,309	686,134
Accounts payable and accrued liabilities	2,205,589	1,867,192
Accounts payable and accrued liabilities, related parties	107,502	132,407
Unearned revenue	68,447	73,495
Payable for indemnification	1,376,084	1,376,084
Convertible notes, net of discounts	482,290	494,708
Convertible notes, related parties, net of discounts	75,000	75,000
Derivative liability, note conversion feature	483,535	658,453
Total liabilities	8,986,436	7,924,434
Commitments and contingencies	'	'
Stockholders' deficit:	'	'
Series 2006 Preferred stock, $0.001 par value, 5,000,000 shares authorized; 1,000,000 shares issued and outstanding	1,000	1,000
Common stock, $0.001 par value; 250,000,000 shares authorized; 150,426,703 and 107,039,034 shares issued and outstanding, respectively	150,426	107,039
Additional paid-in capital	37,870,162	37,087,921
Subscriptions receivable	-71,000	-71,000
Accumulated deficit	-46,266,715	-44,363,260
Total stockholders' deficit	-8,316,127	-7,238,300
Total liabilities and stockholders' deficit	670,309	686,134
Yeso Med [Member]	'	'
Current Assets:	'	'
Payable to Yeso-med	$4,187,989	$3,247,095

Balance_Sheets_Unaudited_Paren

Balance Sheets (Unaudited) (Parentheticals) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Preferred stock par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	1,000,000	1,000,000
Preferred stock, shares outstanding	1,000,000	1,000,000
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	150,426,703	107,039,034
Common stock, shares outstanding	150,426,703	107,039,034

Statements_of_Operations_Unaud

Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenue	'	$1,791	$5,048	$3,091
Cost of revenue	'	728	'	1,302
Loss on firm purchase commitment	480,914	491,938	940,894	976,029
Cost of goods sold	480,914	492,666	940,894	977,331
Gross loss	-480,914	-490,875	-935,846	-974,240
Operating expenses:	'	'	'	'
Depreciation and amortization	23,664	23,762	44,053	47,938
General and administrative expenses	311,259	576,856	742,889	1,663,610
Total operating expenses	334,923	600,618	786,942	1,711,548
Operating loss	-815,837	-1,091,493	-1,722,788	-2,685,788
Other income (expense):	'	'	'	'
Interest expense	-261,432	-149,314	-519,972	-266,684
Loss on extinguishment of debt	'	-33,013	'	-39,263
Gain (loss) on change in fair value of derivative liabilities	-19,426	-202,794	216,605	-129,898
Other income (expense), net	122,700	'	122,700	-753
Total other income (expense)	-158,158	-385,121	-180,667	-436,598
Net loss	($973,995)	($1,476,614)	($1,903,455)	($3,122,386)
Net loss per common share - basic and diluted (in Dollars per share)	($0.01)	($0.02)	($0.02)	($0.04)
Weighted average common shares outstanding - basic and diluted (in Shares)	120,025,225	88,631,947	118,874,779	82,079,462

Statements_of_Cash_Flows_Unaud

Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($1,903,455)	($3,122,386)
Depreciation and amortization	44,053	47,938
Stock-based compensation expense	117,478	543,142
Stock options and warrants modification expense	11,716	148,127
Amortization debt discounts	309,090	233,337
Non-cash interest expense related to conversion feature of notes payable	129,460	'
Loss on extinguishment of debt	'	39,263
(Gain) loss on change in fair value of derivative liabilities	-216,605	129,898
Change in operating assets and liabilities:	'	'
Inventories	-1,249	6,352
Prepaid expenses and other current assets	-3,387	1,927
Accounts payable and accrued liabilities	1,329,545	1,378,443
Accounts payable and accrued liabilities - related parties	-24,905	84,152
Unearned revenue	-5,048	'
Payable for indemnification	'	19,535
Net cash used in operating activities	-213,307	-490,272
Cash flows from investing activities:	'	'
Payments for license and patents	-7,637	-5,982
Net cash used in investing activities	-7,637	-5,982
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock through exercise of stock options and warrants	20,000	95,000
Proceeds from issuance of notes for cash	216,900	402,500
Net cash provided by financing activities	236,900	497,500
Net change in cash	15,956	1,246
Cash at beginning of period	932	54
Cash at end of period	16,888	1,300
Supplemental disclosure of cash flow information:	'	'
Interest paid	'	0
Income taxes paid	0	0
Non-cash financing and investing activities:	'	'
Common stock issued for conversion of debt	378,615	379,443
Debt discount on convertible notes	$210,046	$309,664

Note_1_Basis_of_Presentation_D

Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassification	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	'
	Note 1 – Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassification
	Basis of Presentation
	The accompanying financial statements include the accounts of Revolutions Medical Corporation, a Nevada corporation. Unless the context otherwise requires, references to the “Company”, “RevMed”, “our”, “we”, and “us” mean Revolutions Medical Corporation.
	The Company follows accounting standards set by the Financial Accounting Standards Board (“FASB”). The FASB establishes accounting principles generally accepted in the United States (“GAAP”). Rules and interpretive releases of the U.S. Securities and Exchange Commission (“SEC”) under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants, which the Company is required to follow. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codification (“ASC”), which serves as a single source of authoritative non-SEC accounting and reporting standards to be applied by nongovernmental entities.
	Description of Business
	RevMed endeavors to design, develop and commercialize auto retractable vacuum safety syringes.  Our present product development effort is focused on the RevVac™ Auto Retractable Vacuum Safety Syringe (“RevVac™ Safety Syringe”), which is designed specifically to reduce accidental needle stick injuries and lower the spread of blood borne diseases.  The Company also has developed a suite of proprietary Magnetic Resonance Imaging (“MRI”) software tools consisting of RevColor™, Rev3D™, and RevDisplay™.  These tools are designed to enhance general diagnostic confidence through education and research use and in the future the Company believe will have specific commercial applications. The Company’s administrative facilities are located in Charleston, South Carolina and its primary manufacturing facility is located in Wuxi, China.
	The accompanying unaudited interim financial statements of Revolutions Medical Corporation have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”), and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s annual report for the year ended December 31, 2013 on Form 10-K filed on April 14, 2014.
	In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosure contained in the audited consolidated financial statements for the most recent fiscal year ended December 31, 2013 have been omitted.
	Significant Accounting Policies
	Cash and Cash Equivalents
	The Company considers highly liquid investments (those readily convertible to cash) purchased with original maturity dates of three months or less to be cash equivalents.
	Accounts Receivable
	The Company records trade receivables when revenue is recognized.  The Company’s allowance for doubtful accounts is primarily determined by review of specific trade receivables.  Those accounts that are doubtful of collection are included in the allowance.  These provisions are reviewed to determine the adequacy of the allowance for doubtful accounts.  Trade receivables are charged off when there is certainty as to their being uncollectible.  Trade receivables are considered delinquent when payment has not been made within contract terms.
	The Company requires certain distributors to make a prepayment prior to beginning production or shipment of their order.  Distributors may apply such prepayments to their outstanding invoices or pay the invoice and continue to carry forward the deposit for future orders.  Such amounts are included in unearned revenue on the balance sheets.  The Company records an allowance for estimated returns as a reduction to accounts receivable and gross profit.  To date, returns have been immaterial.
	Inventory
	Inventory includes only finished goods and are valued at the lower of cost or market, with cost being determined using weighted average cost.  The Company compares the average cost to the market price and records the lower value.  Management considers such factors as the amount of inventory on hand and in the distribution channel, estimated time to sell such inventory, the shelf life of inventory, and current market conditions when determining excess or obsolete inventories.  A reserve is established for any excess or obsolete inventories or they may be written off. As of June 30, 2014 and December 31, 2013, no allowance for inventory was recorded.
	Property and Equipment
	Property and equipment, including significant improvements, are stated at cost. Expenditures for maintenance and repairs are charged to operating expenses as incurred. When properties are retired or otherwise disposed of, the cost of the asset and the related accumulated depreciation are removed from the accounts with the resulting gain or loss being reflected in results of operations.
	Depreciation and amortization expense is recorded on a straight-line basis over the estimated useful life of the asset as listed below:
	Asset Category		Useful Lives
	Machinery and equipment (years)		5
	Furniture and fixtures (years)		7
	Leasehold improvements		Shorter of leasehold improvement life or remaining term of lease
	Intangibles
	Intangible assets include patents and trademarks, which are valued at cost and amortized on a straight-line basis over periods varying from 17 to 20 years.
	Impairment of Long-lived Assets
	The Company reviews the carrying value of the long-lived assets periodically to determine if facts and circumstances exist that would suggest that assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation are changes in market position and profitability. If facts and circumstances exist which may indicate impairment, the Company will prepare a projection of the undiscounted cash flows of the asset group and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair value.
	Beneficial Conversion Feature
	From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital.  The debt discount is amortized to interest expense over the life of the note using the effective interest method.
	Derivative Instruments
	Derivatives are measured at their fair value on the balance sheet.  In determining the appropriate fair value, the Company uses the Black-Scholes-Model option pricing model (“Black-Scholes Model”).  Changes in fair value are recorded in the statement of operations.
	Fair Value of Financial Instruments
	The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. exit price), in an orderly transaction between market participants at the measurement date.  The Company categorizes its assets and liabilities measured at fair value based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are classified as follows:
	●	Level 1 – quoted prices in active markets for identical assets or liabilities.
	●	Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.
	●	Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.
	The following table summarizes fair value measurements by level at June 30, 2014, for assets and liabilities measured at fair value on a recurring basis:
			Level 1		Level 2		Level 3		Total
	Payable for indemnification		$	—	$	1,376,084	$	—	$	1,376,084
	Derivative liability		$	—	$	—	$	483,535	$	483,535
	The following table summarizes fair value measurements by level at December 31, 2013, for assets and liabilities measured at fair value on a recurring basis:
			Level 1		Level 2		Level 3		Total
	Payable for indemnification		$	—	$	1,376,084	$	—	$	1,376,084
	Derivative liability		$	—	$	—	$	658,453	$	658,453
	Revenue Recognition
	Revenue is recognized for sales when title and risk of ownership passes to the customer, generally upon shipment from the manufacturing facility in Wuxi, China or from our warehouse facility in Ladson, South Carolina; when the price is fixed or determinable; and when collection is reasonably assured.
	Share-based Compensation
	The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes Model and value of common shares based on the trading price on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.
	Income Taxes
	The Company uses the liability method of accounting for income taxes. Under the liability method, deferred taxes are determined based on the differences between the financial statement and tax basis of assets and liabilities at enacted tax rates in effect in the years in which the differences are expected to reverse.
	Earnings (Loss) Per Common Share
	Basic net income (loss) per common share is calculated by dividing net income (loss) available to common stockholders for the period by the weighted average shares of common stock outstanding during the period. Diluted net income per common share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. The calculation of diluted income (loss) per common share assumes the dilutive effect of stock options, warrants and any other potentially dilutive securities outstanding. During a loss period, the potentially dilutive securities have an anti-dilutive effect and are not included in the calculation of dilutive net loss per common share. For the six months ended June 30, 2014, potentially issuable shares, including options and warrants to purchase 22,749,008 shares of the Company’s common stock and notes payable convertible to 103,088,486 shares of the Company’s common stock have been excluded from the calculation. For the six months ended June 30, 2013, potentially issuable shares, including options and warrants to purchase 14,113,003 shares of the Company’s common stock and notes payable convertible to 19,603,263 shares of the Company’s common stock, have been excluded from the calculation.
	Subsequent Events
	The Company has evaluated all transactions occurring between the six months ended June 30, 2014, through the date of issuance of the financial statements for subsequent event disclosure consideration.
	Critical Accounting Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from those estimates.
	Recent Accounting Standards
	In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders’ equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company evaluated and adopted ASU 2014-10 for the reporting period ended June 30, 2014.

Note_2_Going_Concern

Note 2 - Going Concern	6 Months Ended
	Jun. 30, 2014
Going Concern [Text Block] [Abstract]	'
Going Concern [Text Block]	'
	Note 2 – Going Concern
	The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has not established significant sources of revenue to fund the development of its business and pay operating expenses, resulting in a cumulative net loss of $46,266,715 for the period from inception (August 16, 1996) to June 30, 2014 and a working capital deficit of $8,683,417 at June 30, 2014. The ability of the Company to continue as a going concern during the next year depends on successful sales of its RevVac™ Safety Syringe and completion of the Company’s capital raising efforts to fund the development of its 1ml, 5ml and 10ml auto-retractable vacuum safety syringes. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note_3_Property_And_Equipment

Note 3 - Property And Equipment	6 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	Note 3 – Property and Equipment
	Property and equipment consisted of the following:
		June 30,			December 31,
		2014			2013
	Equipment	$	353,235		$	353,235
	Leasehold improvement		44,000			44,000
	Furniture		49,147			49,147
			446,382			446,382
	Less accumulated depreciation		(218,326	)		(176,193	)
		$	228,056		$	270,189
	For the six months ended June 30, 2014 and 2013, the Company recognized depreciation expense related to property and equipment of $42,133 and $43,234, respectively.

Note_4_Intangibles

Note 4 - Intangibles	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	Note 4 – Intangibles
	Intangibles consisted of the following:
		June 30,			December 31,
		2014			2013
	Patent	$	192,543		$	184,906
	Less accumulated amortization		(53,309	)		(51,389	)
		$	139,234		$	133,517
	The Company own one US patent on its vacuum safety blood drawing device issued in 2003. The Company owns two US patents on its RevVac™ auto retractable vacuum safety syringe, the first issued in January 2005 and the second issued in January 2009 (see Note 10). The RevVac™ auto retractable vacuum safety syringe has international patents issued in China, Japan, Mexico, Australia, Taiwan and pending issuance in Canada and European Union. The Company filed US and international Patent Cooperation Treaty provisional patents on vacuum auto retraction designs for a prefilled safety syringe in 2011 and 2012, respectively. In 2013, the Company has decided not to pursue the issuance of its imaging segmentation software patents as written but has made improvements to the software technology and intends to file new provisional patents and copyright protection on these software improvements in the future.
	For the six months ended June 30, 2014 and 2013, the Company recognized amortization expense of $1,920 and $4,704, respectively.

Note_5_Accounts_Payable_and_Ac

Note 5 - Accounts Payable and Accrued Liabilities	6 Months Ended
	Jun. 30, 2014
Note 5 - Accounts Payable and Accrued Liabilities [Line Items]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	Note 5 – Accounts Payable and Accrued Liabilities
	Accounts payable and accrued liabilities consisted of the following:
		30-Jun-14		31-Dec-13
	Accounts payable	$	600,953	$	565,127
	Accrued payroll liabilities and related penalties		596,475		607,134
	Accrued salary		671,280		418,440
	Accrued interest		217,803		158,869
	Other accruals		119,078		117,622
		$	2,205,589	$	1,867,192
	As of June 30, 2014 and December 31, 2013, the Company accrued $596,475 and $607,134, respectively, pursuant to state and federal payroll tax liabilities and related penalties.  Although the Company plans to settle these amounts, there is no assurance that its efforts to settle will be successful.  Tax liens in the aggregate amount of $6,164 were filed against the Company as of December 31, 2013 by the South Carolina Department of Revenue due to these delinquent payments and failure to file the required tax forms.  Tax liens in the aggregate amount of $675,057 were filed against the Company as of April 15, 2014 by the Internal Revenue Service due to these delinquent payments and failure to file the required tax forms. On May 26, 2014, the Internal Revenue Service reduced the assessment of total amount owed by approximately $88,000. The Company has filed all required payroll tax forms as of the date of this filing and is negotiating with the taxing authorities to resolve these liabilities.
Yeso Med [Member]	'
Note 5 - Accounts Payable and Accrued Liabilities [Line Items]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	Note 6 – Payable to Yeso-med
	On December 1, 2011, the Company entered into a 5-year agreement with Wuxi Yushou Medical Appliance Co., Ltd (“Yeso-med”). Pursuant to the agreement, commencing from the date that Yeso-med demonstrates to the Company’s satisfaction that it has the capacity to commence regular production of the syringes in the 3ml size in the minimum amount of at least 2,500,000 units per month, the Company will place orders of at least 2,500,000 units per month for the term of this agreement. If the Company does not place with Yeso-med the minimum order for a single month, Yeso-med shall have the right to receive payments from the Company equal to 50% of the supply price of each unit below the minimum order amount required for that month.  The Company has the right to have the amount paid under this requirement to serve as payment against future orders provided the quantity ordered exceeds the minimum quantity for that month. In July 2012, Yeso-med met the capacity requirement. However, the Company has not yet placed an order as of June 30, 2014.  As of June 30, 2014 and December 31, 2013, a payable was recorded to Yeso-med related to this minimum purchase requirement of $3,689,969 and $2,749,075, for which no payments have been made, respectively. During the six months ended June 30, 2014 and 2014, $940,894 and $976,029 was recorded as a loss on firm purchase commitments.
	The payable to Yeso-med also included amounts due for product purchased of $208,501 and amounts due for equipment purchased of $289,519 as of June 30, 2014 and the same amount at December 31, 2013, respectively.

Note_7_Payable_for_Indemnifica

Note 7 - Payable for Indemnification (Payable for Indemnification [Member])	6 Months Ended
	Jun. 30, 2014
Payable for Indemnification [Member]	'
Note 7 - Payable for Indemnification [Line Items]	'
Short-term Debt [Text Block]	'
	Note 7 – Payable for Indemnification
	On February 5, 2009, the Company entered into an Indemnification Settlement Agreement with Gifford M. Mabie, founder and former Chief Executive Officer of the Company. Pursuant to the agreement, the Company agreed to indemnify Mr. Mabie for the payment of penalties, prejudgment interest and post-judgment interest to the SEC that is part of the Final Judgment, dated March 11, 2005, in SEC v. Maxxon, Inc., Gifford M. Mabie, Jr., Thomas R. Coughlin, Jr. 02-CV-975-H(J) which resulted from actions taken in good faith by Messrs. Mabie and Coughlin in the performance of duties as an officer and directors of the Company.  The payment amount stated in the Final Judgment was $1,088,067.
	The agreement specifies that the Company is to periodically issue shares of its common stock to a special account for Mr. Mabie so that shares can be sold each day the market is open until the liability is satisfied.  The special account was initially funded by common stock owned by Mr. Mabie. The total number of shares sold from the special account is limited to 5% of the total trading volume each day. A percentage equal to Mr. Mabie’s federal and state tax liabilities up to a maximum of 40% will be retained by the brokerage firm administering the special account and remitted to the Internal Revenue Service and to the Oklahoma Tax Commission or the tax commission having jurisdiction in the state in which Mr. Mabie resides. In the event that Mr. Mabie is entitled to a tax refund, the refund will be remitted to the SEC.
	On December 14, 2010, the Company issued 400,000 shares of the Company’s common stock, initially valued at $184,000, to the special account. An additional 400,000 shares were issued to the special account on March 15, 2012 with a value of $140,560 determined based upon the 10-day average share price prior to the date of issuance.  At each reporting date, the Company revalues the shares held in the special account and adjusts the outstanding balance. Net increases and decreases in the value of the Company’s common shares held in the special account are recorded in the current period statement of operations. As of June 30, 2014 and December 31, 2013, the remaining principal balance, including the estimated taxes, to be paid was $1.4 million, based upon the Company’s valuation of the stock. For the six months ended June 30, 2014 and 2013, the net loss related to shares of the Company’s common stock held in the special account was $0 and $19,535, respectively. As of June 30, 2014, there were 301,463 shares of the Company’s common stock held in the special account.

Note_8_Convertible_Notes

Note 8 - Convertible Notes	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 8 – Convertible Notes
	Convertible notes consisted of the following:
		June 30,			December 31,
		2014			2013
	Convertible Promissory Note Payable to JMJ Financial, unsecured, one time interest charge of 8%, due on February 22, 2014 (in default)		191,663			191,663
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on May 19, 2014		-			35,000
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on July 23, 2014		-			42,500
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on September 12, 2014		-			47,500
	Convertible Promissory Note Payable to Carebourn Capital LP, unsecured, interest rate of 8% per annum, with payment due on June 30, 2014		-			32,500
	Convertible Promissory Note Payable to Carebourn Capital LP, unsecured, interest rate of 8% per annum, with payment due on July 29, 2014		-			10,000
	Convertible Promissory Note Payable to Carebourn Capital LP, unsecured, interest rate of 8% per annum, with payment due on August 29, 2014 (currently working with the creditor to convert this note into shares)		17,500			17,500
	Convertible Promissory Note Payable to TCA Global Credit Master Fund, LP, unsecured by all of the Company's assets, interest rate of 12% per annum, with payment due monthly until April 26, 2014 (in default)		189,844			189,844
	Convertible Promissory Note Payable issued in the course of a private placement to individual, unsecured, interest rate of 12% per annum, with payment due on April 9, 2014 or subsequently on demand by holder		-			140,862
	Convertible Promissory Note Payable issued in the course of a private placement to individual, unsecured, interest rate of 8% per annum, with payment due on September 3, 2014 (currently working with the creditor to convert this note into shares)		35,000			35,000
	Convertible Promissory Note Payable issued in the course of a private placement to individual, unsecured, interest rate of 8% per annum, with payment due on August 26, 2014 (currently working with the creditor to convert this note into shares)		75,000			75,000
	Convertible Promissory Note Payable to Carebourn Partners LLC, unsecured, interest rate of 8% per annum, with payment due on August 29, 2014 (currently working with the creditor to convert this note into shares)		15,000			-
	Convertible Promissory Note Payable to Booski Consulting LLC, unsecured, interest rate of 8% per annum, with payment due on December 17, 2014		5,000			-
	Convertible Promissory Note Payable to Linrick Industries LLC, unsecured, interest rate of 8% per annum, with payment due on December 17, 2014		5,000			-
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on December 4, 2014		53,000			-
	Convertible Promissory Note Payable to Carebourn, unsecured, interest rate of 12% per annum, with payment due on January 15, 2015		27,500			-
	Convertible Promissory Note Payable to KBM Worldwide, unsecured, interest rate of 8% per annum, with payment due on February 9, 2015		38,900			-
	Convertible Promissory Note Payable to Carebourn, unsecured, interest rate of 12% per annum, with payment due on January 15, 2015		52,500			-
			705,907			817,369
	Less: debt discount		(148,617	)		(247,661	)
		$	557,290		$	569,708
	JMJ Financial
	On February 22, 2011, the Company issued a convertible promissory note in the amount of $1,050,000 to JMJ Financial, Inc. (“JMJ”). The note bears interest in the form of a one-time interest charge of 8%, payable with the note’s principal amount on the maturity date, February 22, 2014. The note is convertible to the Company’s common stock at a price equal to 70% of the average of the three lowest closing market prices of the Company’s common stock for the 20 trading days prior to the conversion date. In connection with the note, the Company entered into a registration rights agreement with JMJ to provide JMJ registration rights for common shares underlying this note. The note will only be funded when the conversion price calculated on each payment date is equal to or greater than $0.015 per share and there are sufficient shares remaining in the registration statement. The principal amount owed to JMJ at June 30, 2014 and December 31, 2013 was $191,663 under the convertible promissory note. The Company analyzed the JMJ note for derivative accounting consideration and determined that the note qualifies for accounting treatment as a financial derivative and recorded an initial discount of $450,000 on the issuance date. During the six months ended June 30, 2014 and 2013, the Company recorded $11,229 and $39,671 of interest expense related to the amortization of the debt discount. At June 30, 2014 and December 31, 2013, there was $0 and $11,229, respectively, of unamortized debt discount related to the JMJ notes. The Company is currently in litigation with JMJ. See Note 10.
	KBM Worldwide
	On May 5, 2014, the Company issued a convertible promissory note to KBM Worldwide Inc., an affiliate of Asher, for proceeds of $38,900 (the “KBM Note”). The note is convertible to the Company’s common stock at a conversion price equal to the greater of (1) 53% multiplied by the average of the lowest three trading days for the Company’s common stock during the 10 day trading period ending on the latest completed trading day prior to the conversion date and (2) a fixed conversion price of $0.00005 per share. The Company analyzed the KBM Note for derivative accounting consideration and determined that the conversion feature of these notes qualify for accounting treatment as a financial derivative. The conversion feature of the note was valued at $32,046 on the issuance date. During the six months ended June 30, 2014, the Company recognized $6,098 of interest expense related to the amortization of the debt discount on the KBM notes. At June 30, 2014, there was $25,948 of unamortized discount related to the unconverted KBM notes with a total principal balance of $38,900.
	Asher Enterprises
	On February 28, 2014, the Company issued convertible promissory notes to Asher Enterprises for proceeds of $53,000 in cash (the “2014 Asher Note”). The note is convertible to the Company’s common stock at a conversion price equal to the greater of (1) 55% multiplied by the average of the lowest three trading prices for the Company’s common stock during the 10 trading day period ending on the latest completed trading day prior to the conversion date and (2) a fixed conversion price of $0.00005 per share. The Company analyzed the 2014 Asher Note for derivative accounting consideration and determined that the conversion feature of these notes qualify for accounting treatment as a financial derivative. The conversion feature of the note was valued at $72,298 on the issuance date. As a result, the note was fully discounted and the fair value of the conversion feature in excess of the principal amount allocated to the note in the amount of $19,298 was expensed immediately as additional interest expense. During the six months ended June 30, 2014, the Company recognized $117,662 of aggregate interest expense related to the amortization of the debt discount on all Asher notes. At June 30, 2014, there was $29,824 of unamortized discount related to the unconverted Asher notes with a total principal balance of $53,000. During the six months ended June 30, 2014, Asher Enterprises converted principal of $125,000 with accrued interest related to notes issued in 2013 into 20,052,189 shares of the Company’s common stock.
	Carebourn Capital
	On March 17, May 15, and June 19, 2014, the Company issued convertible promissory notes to Carebourn Capital for proceeds of $15,000, $27,500, and $52,500 in cash, respectively, (“2014 Carebourn Note”). The notes are convertible to the Company’s common stock at a conversion price equal to the greater of (1) 55% multiplied by the average of the lowest three trading prices for the Company’s common stock during the 10 trading day period ending on the latest completed trading day prior to the conversion date (2) a fixed conversion price of $0.00009 per share. The Company analyzed the 2014 Carebourn Notes for derivative accounting consideration and determined that the conversion feature of these notes qualify for accounting treatment as a financial derivative. The conversion features of these notes were valued at $165,785 on the issuance date. As a result, the notes were fully discounted and the fair value of the conversion feature in excess of the principal amount allocated to the note in the amount of $70,785 was expensed immediately as additional interest expense. During the six months ended June 30, 2014, the Company recognized $59,259 of aggregate interest expense related to the amortization of the debt discount on all Carebourn notes. At June 30, 2014, there was $81,005 of unamortized discount related to the unconverted Carebourn notes with a total principal balance of $112,500. During the six months ended June 30, 2014, Carebourn converted principal of $42,500 with accrued interest related to notes issued in 2013 into 5,693,720 shares of the Company’s common stock.
	TCA Global Credit Master Fund, LP
	On April 26, 2013, the Company entered into a securities purchase agreement with TCA, pursuant to which, TCA shall purchase from the Company up to $2,000,000 of senior secured convertible redeemable debentures (the “Debentures”). The Debentures will be purchased in a series of closings and pursuant to the first such closing, TCA purchased that certain senior convertible redeemable debenture in the amount of $250,000.
	The Debentures were issued at 7% original issue discount and the discount of $17,500 is amortized over one year, the term of the Debentures, using the straight-line method which approximates the effective interest method due to the short term nature of the note. The note bears interest at a rate of 12% per annum and the Company shall make monthly payments of principal and interest commencing on May 26, 2013 with the first two payments only including interest. During 2013, the Company made principal payments of $77,656 and interest payments of $11,781 to TCA. As of June 30, 2014, the Company was not in compliance with the financial covenants of this credit facility as it was unable to make the scheduled principal and interest payments since November 2013. On February 24, 2014, TCA filed in a Florida court to seek unpaid monthly payments, default interest and penalties related to this facility as part of the credit facility agreement. The Company became delinquent on payments and was notified of default on January 24, 2014. The Company is working with TCA on an amicable payment of past due amounts and seeks to pay the amount left owed to TCA after it receives disbursements from legal settlements, issuance of additional shares, and or proceeds from anticipated sales.
	The Debentures are convertible at a price determined by multiplying 85% of the average daily volume weighted average price of the Company’s common stock during the five business days immediately preceding the date of conversion. The Company analyzed the Debentures for derivative accounting consideration and determined that the Debentures qualify for accounting treatment as a financial derivative. The conversion feature of the Debentures was valued at $218,053 on the issuance date and recorded as debt discount. As of June 30, 2014, the debt discount was fully amortized.
	The Company also issued to TCA 9,375,000 shares, which were pledged as security for the securities purchase agreement and was held with an escrow agent until such time as the full payment and performance of all of the obligations of the Company have been satisfied in accordance with the terms of the agreement. The Company also granted TCA the right to vote and receive dividends during the period the 9,375,000 shares were held by TCA. The Company recorded shares issued at par value of $9,375 with an offset to additional paid-in capital.
	On May 9, 2013, the Company issued 2,000,000 restricted shares to pay for the $100,000 facility fee pursuant to the 2013 TCA securities purchase agreement entered into on April 26, 2013 with TCA. TCA will return all remaining shares to the Company if total net proceeds of $100,000 are reached. The Company will pay cash or issue additional shares if a total of 2,000,000 shares are sold and net proceeds do not total $100,000. The Company has the right to redeem any shares then in TCA’s possession for an amount equal to the $100,000 facility fee less any net proceeds received by TCA from the sales of the Company’s shares. On the issuance date, the Company recorded an expense of $160,000 for the issuance of 2,000,000 shares based on the stock price. At December 31, 2013, TCA had not sold any of the 2,000,000 shares. Accordingly, the Company accrued an additional expense of $60,000 which represents the difference between the $100,000 facility fee and the fair market value of the 2,000,000 shares at December 31, 2013 of $0.02 per share. All shares were sold by TCA during the six months ended June 30, 2014. TCA received approximately $79,000 from the sales of these shares. The Company has yet to issue additional shares for the remaining unpaid fee.
	2013 Individual Convertible Notes Payable
	On September 3, 2013, the Company issued a $35,000 convertible note to an individual. The note matures one year from the date of issuance. Interest accrues at the rate of 8% per year on the outstanding principal amount to be paid at maturity. The conversion provisions of this note are the same as the 2012 Individual Convertible Notes as described above. The Company analyzed the note for derivative accounting consideration and determined that the conversion feature of the note qualifies for accounting treatment as a financial derivative. The conversion feature of this note was valued at $37,837 on the issuance date. As a result, the note was fully discounted and the fair value of the conversion feature in excess of the principal amount allocated to the note of $2,837 was expensed immediately as additional interest expense. During the six months ended June 30, 2014, the Company recognized $17,740 of interest expense related to the amortization of the debt discount. At June 30, 2014, there was $5,658 of unamortized discount related to the note. In connection with the issuance of the note, warrants to purchase 140,000 shares of the Company’s common stock at $0.25 per share and 70,000 shares of the Company’s common stock at $0.50 per share were issued to the note holder. These warrants were valued at $2,588 using the Black-Scholes Model.
	On October 9, 2013, the Company issued six convertible notes in an aggregate amount of $140,862 to an individual to settle amounts owed by the Company for legal services rendered to the Company. The notes are callable at any time by the holder subsequent to the six month anniversary of the issuance date. Interest accrues at the rate of 12% per year on the outstanding principal amount to be paid at maturity. The principal amount of the note and accrued interest are convertible into the Company’s common stock at a conversion price equal to the average five trading day closing price of the Company’s common stock during the five trading days immediately prior to the conversion date multiplied by two. The Company analyzed the notes for derivative accounting consideration and determined that the conversion feature of the notes qualifies for accounting treatment as a financial derivative. The conversion feature of the notes was valued at an aggregate amount of $35,709 on the issuance date. During the six months ended June 30, 2014, the Company recognized $19,425 of interest expense related to the amortization of the debt discount. At June 30, 2014, the debt discount was fully amortized. During the six months ended June 30, 2014, $140,862 principal of the notes issued in 2013 with accrued interest were converted into 9,647,529 shares of the Company’s common stock.
	On March 17, 2014, the Company issued convertible notes to two individuals for proceeds of $15,000 each in cash. The notes mature nine months from the date of issuance. Interest accrues at the rate of 8% per year on the outstanding principal amount to be paid at maturity. The notes are convertible to the Company’s common stock at a conversion price equal to 55% multiplied by the average of the lowest three trading prices for the Company’s common stock during the 10 trading day period ending on the latest completed trading day prior to the conversion date. The Company analyzed the notes for derivative accounting consideration and determined that the conversion feature of the notes qualify for accounting treatment as a financial derivative. The conversion feature of the notes was valued at $69,376 on the issuance date. As a result, the note was fully discounted and the fair value of the conversion feature in excess of the principal amount allocated to the note of $39,376 was expensed immediately as additional interest expense. During six months ended June 30, 2014, the Company recognized $23,818 of interest expense related to the amortization of the debt discount. At June 30, 2014, there was $6,182 of unamortized discount related to the note. During the six months ended June 30, 2014, the note holders converted principal of $20,000 with accrued interest into 4,705,351 shares of the Company’s common stock.

Note_9_Derivatives_Note_Conver

Note 9 - Derivatives - Note Conversion Feature (Note Conversion Feature [Member])	6 Months Ended
	Jun. 30, 2014
Note Conversion Feature [Member]	'
Note 9 - Derivatives - Note Conversion Feature [Line Items]	'
Derivatives and Fair Value [Text Block]	'
	Note 9 – Derivatives – Note Conversion Feature
	Due to the conversion feature contained in some of the notes that the Company has issued, the actual number of shares of common stock that would be required if a conversion of the notes was made through the issuance of the Company’s common stock cannot be predicted, and the Company could be required to issue an amount of shares that may cause it to exceed its authorized share amount. As a result, the conversion feature requires derivative accounting treatment and will be bifurcated from the note and “marked to market” each reporting period through the income statement. The fair value of the conversion feature of these notes was recognized as a derivative liability instrument and will be measured at fair value at each reporting period. In determining the fair value, the Company uses the Black-Scholes Model. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes Model.
	The following is a summary of the activity of the derivative liability for the six months ended June 30, 2014:
	Fair value at December 31, 2013	$	658,453
	Decrease in value		(216,605	)
	Addition		339,506
	Reclassification from liability to equity as a result of note conversions		(297,819	)
	Fair value at June 30, 2014	$	483,535
	The derivative liability was valued using the Black-Scholes Model with the following assumptions:
		June 30,			December 31,
		2014			2013
	Risk free interest rate		0.11%			0.13%
	Expected life (years)		0.01 to 0.61			0.07 to 0.7
	Dividend Yield		0%			0%
	Volatility		270% to 302%			256% to 394%
		Various issuance dates during the
		Six months ended			Year ended
		June 30,			December 31,
		2014			2013
	Risk free interest rate		0.09 to 0.13%			0.10 to 0.15%
	Expected life (years)		0.45 to 0.77			0.50 to 0.99
	Dividend Yield		0%			0%
	Volatility		251% to 280%			213% to 293%

Note_10_Commitments_and_Contin

Note 10 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 10 – Commitments and Contingencies
	KVM Capital Partners Investment Agreement
	On June 11, 2013, the Company entered into an Investment Agreement with KVM Capital Partners (“KVM”), whereby the parties also agreed to enter into a registration rights agreement. Pursuant to the terms of the investment agreement, for a period of 36 months commencing on the trading day immediately following date of effectiveness of the Registration Statement, KVM will commit to purchase up to $1,500,000 of the Company’s common stock, pursuant to a notice from the Company (“Puts”), covering the Registrable Securities (as defined below). The purchase price of the Shares under the investment agreement is equal to a 22.5% percent discount to the average of the three lowest closing bids during the last seven trading days after the Company delivers to KVM a Put notice in writing requiring KVM to purchase shares of the Company, subject to the terms of the investment agreement.
	The Registrable Securities include (1) shares of the Company’s common stock and (2) any shares of capital stock issued or issuable with respect to the Company’s common stock, if any, as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise, which have not been (1) included in the registration statement that has been declared effective by the SEC, or (2) sold under circumstances meeting all of the applicable conditions of Rule 144 (or any similar provision then in force) under the 1933 Act.
	As further consideration for KVM entering into and structuring the investment agreement, the Company paid to KVM a $10,000 fee by issuing to KVM 250,000 restricted shares of its common stock on June 11, 2013. As of June 30, 2014, a registration statement has not been declared effective by the SEC and, accordingly, has no availability under this agreement.
	Maxxon/Globe Joint Venture Agreement
	In September 2005, the Company filed a patent on its RevVac™ Safety Syringe with Globe Med Tech which gave a 50% ownership of this patent to the Company and 50% to Globe Med Tech. On November 3, 2005, the Company (f.k.a. Maxxon, Inc.,) and Globe Med Tech, Inc. (“Globe”) entered into a definitive joint venture agreement (the “Joint Venture Agreement”) to patent, develop, manufacture, market and distribute safety needle products throughout the world.  The Company and Globe each owned 50% of the joint venture.   The Company contributed its safety syringe technology and patent rights related thereto and Globe contributed its safety syringe IV catheter and patent rights related thereto.  In connection with the Joint Venture Agreement, the Company issued restricted shares of its common stock, valued at $625,066, to Globe.  Subsequent to December 31, 2006, the Company ended the Joint Venture Agreement and cancelled the restricted shares of common stock that were issued to Globe pursuant to the agreement.  The above noted patent was issued on January 13, 2009.
	On March 1, 2007, the Company filed a lawsuit in the District Court of Tulsa County, Oklahoma against Globe to rescind, terminate and seek monetary damages for the non-fulfillment and breach of the Joint Venture Agreement, and other related agreements, in addition to an accounting of expenditures of funds under the terms and provisions of the agreements.  On October 29, 2008, the Company filed in the District Court of Harris County, Texas, a lawsuit for fraud and contempt of court for Globe and Andy Hu, individually.  On October 21, 2011, the Company was granted its request for summary judgment against Globe and awarded $311,440 and the return of 266,666 shares of the Company’s common stock by a Federal District Court in Tulsa County, Oklahoma.  In addition to the monetary award and the return of the Company’s common stock, Globe is also required to return all syringes, design files, and sample molds to the Company.  Furthermore, the Court ordered that Globe assign to the Company all rights to the patent issued on January 13, 2009 for the RevVac™ Safety Syringe.  Globe is prohibited from claiming any interest or ownership in the Company’s safety vacuum syringes going forward.
	On April 30, 2013, the Company exercised its legal rights under a writ of execution in Harris County, Texas, pursuant to which the Company seized all valuable property from Globe Med Tech’s office including 266,666 restricted shares of common stock of Revolutions Medical, all design and patent files relating to its auto retractable vacuum safety syringe, furniture, computers, phones and other office equipment and information.  Globe’s web hosting company has been notified and ordered under the judgment and writ of execution to shut down Globe’s website until all information and references of ownership, patents and awards regarding the RevVac™ Safety Syringe are removed from the website. The Company will continue to use all available legal means under the judgment until all monies are collected and the judgment is satisfied in full. On August 27, 2013, the Company cancelled the 266,666 shares.
	MIG and SPD
	On September 26, 2012, the Company filed suit in South Carolina Federal District Court against Strategic Product Development ("SPD"), Richard H. Theriault, Vita S. Theriault, Darius R. Theriault, Raminta Theriault, Goddard Technologies, Inc. ("GTI") and others, claiming that the defendants purposely and materially misled and misrepresented capabilities and progress on a variety of initiatives related to the development and manufacture of the Company's RevVac™ Safety Syringe to officers and directors of Revolutions Medical, which caused a delay in its production of approximately one year. The suit further alleges that Richard H. Theriault and other defendants defrauded the Company and misappropriated funds in violation of the United States' Racketeer Influenced and Corrupt Organizations Act and that GTI improperly assigned certain rights to the Company's new provisional patents to SPD without authorization. In February, 2013 the Company changed the venue to the United States District Court of Massachusetts against GTI. On February 17, 2014, the Company amended its claims against GTI and certain employees at Goddard to include negligence and unfair trade practices both in the state of MA and in SC based upon supplemental discovery provided by Goddard’s attorney. Depositions and the jury trial are being scheduled for the second quarter of 2014.
	On January 2, 2013, the Company won its arbitration proceeding concerning its counter claims against Richard Theriault, former manufacturer, Medical Investment Group (“MIG”) and former consultant, SPD.  The monetary award included $770,000 in recoupment of production costs plus interest, legal fees and other arbitration costs, which will total approximately $1 million. In other claims, Theriault was found guilty of fraud in the inducement and breach of contract and was found to have no rights to any of the Company's proprietary technology, files, drawings, designs, patents or products. A panel of the American Arbitration Association (“Arbitrator”) determined that all production mold payments made by the Company to MIG for the manufacturing of production molds had instead been used by Mr. Theriault for other non-production related purposes. The Arbitrator ruled that the only assets in which production was funded by MIG from the Company’s production payments were $10,000 in trial molds. The equipment asset on the balance sheet was reduced by $710,000 and charged to impairment of assets in 2012 as the payments were not associated with a production or trial mold. The $770,000 award is for the recovery of damages related to these production payments.  The gain related to this award will be recorded when collected. The Company has retained counsel in Massachusetts and South Carolina to assist in efforts to collect these damages.
	On February 2, 2013, Richard H. Theriault, MIG, SPD, and other Theriault corporate entities, filed for bankruptcy in Massachusetts under Chapter 11. The South Carolina lawsuit has been temporarily stayed. On March 13, 2013, United States Federal District Court in Massachusetts granted an injunction against Richard H. Theriault and MIG, enjoining and restraining them from transferring or alienating any assets in their possession without approval from the Court. On May 6, 2013, that court upheld its ruling in favor of continuing the injunction. On September 17, 2013 the bankruptcy court allowed the Company to lift the stay to confirm the arbitration judgment in South Carolina.
	On May 7, 2014, the United States Bankruptcy Court for the District of Massachusetts (Eastern Division) entered an Order confirming the First Amended Plan of Reorganization dated February 14, 2014 filed by Richard H. Theriault. The Company expects to receive a payment of approximately $125,000 under the plan. The Company and Mr. Theriault also entered into a Settlement Agreement dated January 29, 2014 (the “Settlement Agreement”) that was part of the Plan. Pursuant to the Settlement Agreement, Mr. Theriault and MIG agreed to pay an aggregate of $320,000 plus accrued interest to the Company in quarterly payments beginning on January 1, 2015. Interest on that amount accrues at 3% beginning as of the date of the Order. The first two payments will be $26,667, the third payment will be $40,000 and each of the final nine payments will be $25,185. In return, the Company agreed to dismiss its pending action in the United States District Court of South Carolina (the “S.C. Action”) against Mr. Theriault, his family members and certain of his companies within 15 days of the Order provided those defendants execute a release of all claims that they have asserted or could have asserted against the Company in the S.C. Action. The Settlement Agreement did not include the Company’s pending adversary proceeding in the Bankruptcy Court against SPD regarding a dispute involving patents for the RevVac™ pre-filled auto-retractable syringes or a release of SPD and Ira Rakatansky in United States District Court of South Carolina. The Company continues to preserve all of its legal rights against SPD.  $122,700 cash collected from this settlement during the six months ended June 30, 2014 was recorded in other income.
	Thomas G. O’Brien
	On October 1, 2012, the Company filed suit in South Carolina Federal District Court against its former President and Director, Thomas G. O'Brien (“O’Brien”), alleging that O'Brien, as a director and officer of the Company, committed fraud, disregarded his fiduciary duties, and breached other obligations owed to the Company and its shareholders, by facilitating and negotiating contracts on behalf of the Company while at the same time sharing confidential Company information with, and receiving bribes from, Richard H. Theriault, SPD, and Medical Investment Group, (MIG). The complaint seeks to recover actual and punitive damages as well as a return of all salary paid to O'Brien under his employment agreement and over 3 million restricted shares.  On January 17, 2013, the South Carolina lawsuit was dismissed without prejudice, so the Company can pursue all of its claims against Thomas G. O'Brien in arbitration. No arbitration case is presently pending between the Company and O’Brien.
	JMJ Financial, Inc.
	A lawsuit was filed against the Company by Justin Keener d/b/a JMJ in Miami-Dade County, Florida on March 15, 2012. The lawsuit claims that the Company breached the terms of the convertible debt agreement by failing to issue shares requested in a stock conversion by JMJ on January 9, 2012 for 1,000,000 shares and on January 30, 2012 for 1,226,049 shares.  JMJ is seeking the delivery of 2,226,049 shares of common stock of the Company, plus costs and prejudgment interest. On August 30, 2012, the Company filed its counterclaims against JMJ, which included fraud by concealment, among other claims. The Company alleges that JMJ had a responsibility and obligation under Florida law to disclose during the negotiations of the agreement the fact that Keener and JMJ had outstanding and current issues with these type of convertible notes with DTC which could do detrimental harm to liquidity and electronic transfer of the Company's stock if DTC eligibility was “chilled”. In the securities trading industry, the loss of eligibility for electronic trading, transfer, and delivery of common stock is known as a “chill”. This would severely hamper future capital raising and harm its current shareholders but would solely benefit Keener and JMJ under the default clauses in this agreement. On March 14, 2013 the Company received a letter from the DTC advising that a “chill” was placed on its stock. All of the JMJ share issuances were among the share issuances that the DTC identified to be reviewed. In July 2013, the Company won its motion to compel discovery from JMJ and Keener to provide all documents related to all financings with public companies that Keener and JMJ were involved, especially companies that DTC put a "chill" on their publicly traded stock and any regulatory actions or rulings against Keener and JMJ. On October 14, 2013, the DTC advised the Company that the “chill” had been lifted. If a positive settlement cannot be negotiated, the Company plans on bringing their counterclaims in a jury trial court proceeding.
	SEC
	On September 20, 2012, the Securities and Exchange Commission (“SEC”) filed a civil complaint in Federal District Court in Georgia against the Company and Rondald L. Wheet, the Company’s current Chief Executive Officer, alleging that between approximately August 2010 and July 2011, the Company and its Chief Executive Officer issued a series of misleading press releases that contained statements designed to convey the impression that, among other things, the Company had finalized the development of a safe and effective syringe, the syringe was slated for imminent mass manufacturing and commercial distribution, and the Company had entered into, or was on the cusp of entering into, binding mass sales and distribution agreements, including a sales agreement with the U.S. Department of Defense. However, contrary to the statements made in the Company’s press releases, the Company had not developed a safe and effective syringe ready for mass manufacturing or commercial distribution, and had not entered into any binding agreements for the sale and distribution of such a final product. The SEC’s complaint further alleges that, through the press releases, the Company artificially inflated the price of the Company’s shares, and that the Company sold shares to a third-party hedge fund at inflated prices. Among other relief, the SEC seeks an order requiring the Company to disgorge approximately $1,000,000 received from its equity line financing from August 2010 through May 2011 with Auctus Private Equity Fund, in addition to other civil penalty amounts, and the SEC is seeking an officer and director bar against its Chief Executive Officer.
	The Company filed its answer on November 8, 2012 and its amended answer on January 21, 2013. The discovery is currently ongoing and no trial date has been set by the court. Because discovery is currently ongoing, the Company is not able to project the possible outcome.
	On August 15, 2014, the Company filed with the Federal District Court in Northern District of Georgia for summary judgment for the dismissal of the SEC case pending against it.
	TCA Global Credit Master Fund, L.P.
	On April 26, 2013 (the “Effective Date”), the Company finalized a securities purchase agreement with TCA. Pursuant to the terms of the purchase agreement, TCA shall purchase from the Company up to $2 million of senior secured convertible redeemable debentures.  The debentures shall be purchased in a series of closings and pursuant to the first such closing, as of the Effective Date, TCA purchased that certain senior convertible redeemable debenture in the amount of $250,000.  The Company’s obligations to TCA under the debentures are secured by that certain security agreement granting TCA an unconditional and continuing first priority security interest in all of the Company’s assets and that certain stock pledge agreement granting TCA a continuing and first priority security interest in certain stock of the Company.
	Under the purchase agreement, as consideration for advisory services provided by TCA to the Company prior to the Effective Date, the Company shall pay to TCA a fee by issuing to TCA that number of shares of the Company’s common stock that equal a dollar amount of $100,000 (the “Advisory Fee Shares”).  It is the intention of the Company and TCA that the value of the Advisory Fee Shares shall equal $100,000.  In the event the value of the Advisory Fee Shares issued to TCA does not equal $100,000 after the sale of all Advisory Fee Shares, the purchase agreement provides for an adjustment provision allowing for necessary action to adjust the number of shares issued.  Additionally, TCA shall receive certain other fees pursuant to the purchase agreement.

Note_11_Preferred_Stock_and_Co

Note 11 - Preferred Stock and Common Stock Transactions	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 11 – Preferred Stock and Common Stock Transactions
	Preferred Stock
	Shares Outstanding: Currently, 1,000,000 shares of preferred stock (“Preferred Stock”) are outstanding. Rondald L. Wheet, the Company’s Chairman and Chief Executive Officer, owns 1,000,000 shares of Series 2006 Preferred Stock.
	Dividends: The holder of the Preferred Stock is entitled to receive, ratably, dividends when, as and if declared by the board of directors out of funds legally available therefore. If any dividend or other distributions are declared on our common stock, then a dividend or other distribution must also be declared on the outstanding Preferred Stock at the same time and on the same terms and conditions, so that each holder of Preferred Stock will receive the same dividend or distribution such holder would have received if the holder had converted his Preferred Stock as of the record date for determining stockholders entitled to receive such dividend or distribution.
	Liquidation Preference: In the event of the liquidation, dissolution or winding up, the holders of Preferred Stock are entitled to receive a liquidation preference of $0.001 for each share of Preferred Stock prior to payment being made to any junior stock.
	Conversion: The holders of Preferred Stock may convert each share into 1 share of common stock.
	Preemption: The holders of Preferred Stock have no preemptive rights and they are not subject to further calls or assessments.
	Voting Rights: The holders of Preferred Stock are entitled to 125 votes for each share of common stock into which their Preferred Stock is then convertible (currently 1 share), voting together with our common stock as a single class. Cumulative voting is not permitted. Upon conversion of a share of Preferred Stock, each share of common stock issued upon the conversion will be entitled to only one (1) vote per share.
	Redemption: There are no redemption or sinking fund provisions applicable to the Preferred Stock.
	2014 Common Stock Transactions
	During the six months ended June 30, 2014, the Company issued 1,000,000 shares of common stock, valued at $36,000 based on the market price on the grant date, for consulting and legal services and issued 1,288,250 shares of common stock, valued at $33,265 based on the market price on the issuance date, to settle accounts payable and accrued payroll. Also, during the six months ended June 30, 2014, the Company issued 1,000,000 shares of common stock for proceeds of $20,000 in cash for the exercise of options issued to consultants. Additionally, during the six months ended June 30, 2014, the Company issued 40,099,419 shares of common stock for the conversions of convertible notes and accrued interest totaling $345,350. The derivative fair value of $297,819 for the conversion feature of these notes was reclassified on the date of conversion to additional paid-in capital.

Note_12_Stock_Options_and_Warr

Note 12 - Stock Options and Warrants Outstanding	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 12 – Stock Options and Warrants Outstanding
	The Company’s 2007 Stock Option Plan, revised July 2011, permits the granting of stock options to its employees, directors, consultants and independent contractors for up to 20 million shares of its common stock.  The Company believes that such awards encourage employees to remain employed by the Company and also to attract persons of exceptional ability to become employees of the Company.  The plan allows the Company to issue either stock options or common shares.
	From time to time, the Company enters into consulting agreements to perform marketing services for the Company as it begins to enter into the production stage for the RevVac™ Safety Syringe. Consultants are obligated under the contract to promote the product within various spheres of influence. These spheres of influence include, but are not limited to, medical product distributors, hospitals, doctors and government agencies.
	Consultants are issued options at a discount to the market price at the date of issuance. The amount to be determined for the consulting expense is determined based upon the options issued using the Black-Scholes Model.
	During the six months ended June 30, 2014, under the terms of the Company’s 2007 Stock Option Plan, 12,500,000 options were issued for consulting services exercisable at $0.01 - $0.50 per share. The options have a term of 1 day to 1 year and vest upon issuance. The aggregate fair value of these options of $81,478 was calculated using the Black-Scholes Model with the following assumptions: (1) discount rate of 0.09% to 0.12% (2) expected life of 0.01 to 1.09 years (3) expected volatility of 199% to 285% and (4) zero expected dividends.
	The following table summarizes the stock option activity:
		Number of			Weighted-		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
		Shares			average
		Under Option			Exercise
					Price
	Outstanding at December 31, 2013		5,500,000			0.12		0.36		-
	Granted		12,500,000			0.01		1.09
	Exercised		(1,000,000	)		0.02
	Forfeited or expired		(500,000	)		0.5
	Outstanding at June 30, 2014		16,500,000			0.03		0.96		-
	At June 30, 2014, there were 6,249,008 warrants outstanding. 4,166,005 of these warrants are exercisable at $0.125 and 2,083,003 are exercisable at $0.25. The warrants exercisable at $0.125 were originally to expire on June 30, 2014, but were modified to expire on September 30, 2014. The warrants exercisable at $0.25 were originally to expire on September 30, 2014, but were modified to expire on December 15, 2014. The Company recorded modification expense of $11,716 for the six months ended June 30, 2014.
	The following table summarizes the warrant activity:
		Number of			Weighted-		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
		Shares			average
		Under Option			Exercise
					Price
	Outstanding at December 31, 2013		6,249,008			0.17		0.34		-
	Granted		-			-		-
	Exercised		-			-
	Forfeited or expired		-
	Outstanding at June 30, 2014		6,249,008			0.17		0.32		-

Note_13_Related_Party_Transact

Note 13 - Related Party Transactions	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 13 – Related Party Transactions
	On September 1, 2009, the Company entered into a 5-year lease agreement with Osprey South, LLC (“Osprey”), to lease its corporate office space at 670 Marina Drive, Suite 301, Building F, Charleston, South Carolina, 29492.  Pursuant to the lease agreement, the Company was to pay Osprey $4,500 per month.  On July 1, 2011, the Company amended the lease agreement to include the office space adjacent to the existing office space.  Under the amended lease agreement, the lease term ends on June 30, 2016, and the Company is to pay Osprey $10,000 per month.  Rondald L. Wheet, the Company’s Chairman and Chief Executive Officer, is the sole member of Osprey.  Rent expense to Osprey was $60,000 and $60,000 for the six months ended June 30, 2014 and 2013, respectively. Rent payable to Osprey was $81,662 and $112,962 as of June 30, 2014 and December 31, 2013, respectively. On July 1, 2014, the Company moved into a new location at 1124 Park West Drive, Mt. Pleasant, South Carolina. The lease for the new location was with a third party.
	The following table sets forth amounts owed by the Company to its executive officers for expenses paid by said officers on behalf of the Company as of June 30, 2014 and December 31, 2013.
		June 30,		December 31,
		2014		2013
	Stephen Wheet, Director of Sales	$	3,205	$	9,890
	Ron Wheet, Chief Executive Officer		9,579		-
	Vincent Olmo, Chief Operating Officer		1,443		942
		$	14,227	$	10,832
	The Company also had a convertible note payable to Mr. Olmo with principal amount of $75,000 and accrued interest of $11,613 at June 30, 2014. The note accrued interest at 8% and is currently in default.

Note_14_Subsequent_Events

Note 14 - Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 14 – Subsequent Events
	On July 29, 2014, the Company issued a convertible promissory note to KBM Worldwide for proceeds of $30,500. The note is convertible to the Company's common stock at a conversion price equal to the greater of (1) 53% multiplied by the average of the lowest three trading prices for the Company's common stock during the 10 trading day period ending on the latest completed trading day prior to the conversion date (2) a fixed conversion price of $0.00005 per share.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies, by Policy (Policies) [Line Items]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation
	The accompanying financial statements include the accounts of Revolutions Medical Corporation, a Nevada corporation. Unless the context otherwise requires, references to the “Company”, “RevMed”, “our”, “we”, and “us” mean Revolutions Medical Corporation.
	The Company follows accounting standards set by the Financial Accounting Standards Board (“FASB”). The FASB establishes accounting principles generally accepted in the United States (“GAAP”). Rules and interpretive releases of the U.S. Securities and Exchange Commission (“SEC”) under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants, which the Company is required to follow. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codification (“ASC”), which serves as a single source of authoritative non-SEC accounting and reporting standards to be applied by nongovernmental entities.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	The Company considers highly liquid investments (those readily convertible to cash) purchased with original maturity dates of three months or less to be cash equivalents.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	'
	Accounts Receivable
	The Company records trade receivables when revenue is recognized.  The Company’s allowance for doubtful accounts is primarily determined by review of specific trade receivables.  Those accounts that are doubtful of collection are included in the allowance.  These provisions are reviewed to determine the adequacy of the allowance for doubtful accounts.  Trade receivables are charged off when there is certainty as to their being uncollectible.  Trade receivables are considered delinquent when payment has not been made within contract terms.
	The Company requires certain distributors to make a prepayment prior to beginning production or shipment of their order.  Distributors may apply such prepayments to their outstanding invoices or pay the invoice and continue to carry forward the deposit for future orders.  Such amounts are included in unearned revenue on the balance sheets.  The Company records an allowance for estimated returns as a reduction to accounts receivable and gross profit.  To date, returns have been immaterial.
Inventory, Policy [Policy Text Block]	'
	Inventory
	Inventory includes only finished goods and are valued at the lower of cost or market, with cost being determined using weighted average cost.  The Company compares the average cost to the market price and records the lower value.  Management considers such factors as the amount of inventory on hand and in the distribution channel, estimated time to sell such inventory, the shelf life of inventory, and current market conditions when determining excess or obsolete inventories.  A reserve is established for any excess or obsolete inventories or they may be written off. As of June 30, 2014 and December 31, 2013, no allowance for inventory was recorded.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	Property and equipment, including significant improvements, are stated at cost. Expenditures for maintenance and repairs are charged to operating expenses as incurred. When properties are retired or otherwise disposed of, the cost of the asset and the related accumulated depreciation are removed from the accounts with the resulting gain or loss being reflected in results of operations.
	Depreciation and amortization expense is recorded on a straight-line basis over the estimated useful life of the asset as listed below:
	Asset Category		Useful Lives
	Machinery and equipment (years)		5
	Furniture and fixtures (years)		7
	Leasehold improvements		Shorter of leasehold improvement life or remaining term of lease
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	'
	Intangibles
	Intangible assets include patents and trademarks, which are valued at cost and amortized on a straight-line basis over periods varying from 17 to 20 years.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	'
	Impairment of Long-lived Assets
	The Company reviews the carrying value of the long-lived assets periodically to determine if facts and circumstances exist that would suggest that assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation are changes in market position and profitability. If facts and circumstances exist which may indicate impairment, the Company will prepare a projection of the undiscounted cash flows of the asset group and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair value.
Derivatives, Policy [Policy Text Block]	'
	Derivative Instruments
	Derivatives are measured at their fair value on the balance sheet.  In determining the appropriate fair value, the Company uses the Black-Scholes-Model option pricing model (“Black-Scholes Model”).  Changes in fair value are recorded in the statement of operations.
Fair Value Measurement, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. exit price), in an orderly transaction between market participants at the measurement date.  The Company categorizes its assets and liabilities measured at fair value based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are classified as follows:
	●	Level 1 – quoted prices in active markets for identical assets or liabilities.
	●	Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.
	●	Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.
	The following table summarizes fair value measurements by level at June 30, 2014, for assets and liabilities measured at fair value on a recurring basis:
			Level 1		Level 2		Level 3		Total
	Payable for indemnification		$	—	$	1,376,084	$	—	$	1,376,084
	Derivative liability		$	—	$	—	$	483,535	$	483,535
	The following table summarizes fair value measurements by level at December 31, 2013, for assets and liabilities measured at fair value on a recurring basis:
			Level 1		Level 2		Level 3		Total
	Payable for indemnification		$	—	$	1,376,084	$	—	$	1,376,084
	Derivative liability		$	—	$	—	$	658,453	$	658,453
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	Revenue is recognized for sales when title and risk of ownership passes to the customer, generally upon shipment from the manufacturing facility in Wuxi, China or from our warehouse facility in Ladson, South Carolina; when the price is fixed or determinable; and when collection is reasonably assured.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Share-based Compensation
	The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes Model and value of common shares based on the trading price on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	The Company uses the liability method of accounting for income taxes. Under the liability method, deferred taxes are determined based on the differences between the financial statement and tax basis of assets and liabilities at enacted tax rates in effect in the years in which the differences are expected to reverse.
Earnings Per Share, Policy [Policy Text Block]	'
	Earnings (Loss) Per Common Share
	Basic net income (loss) per common share is calculated by dividing net income (loss) available to common stockholders for the period by the weighted average shares of common stock outstanding during the period. Diluted net income per common share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. The calculation of diluted income (loss) per common share assumes the dilutive effect of stock options, warrants and any other potentially dilutive securities outstanding. During a loss period, the potentially dilutive securities have an anti-dilutive effect and are not included in the calculation of dilutive net loss per common share. For the six months ended June 30, 2014, potentially issuable shares, including options and warrants to purchase 22,749,008 shares of the Company’s common stock and notes payable convertible to 103,088,486 shares of the Company’s common stock have been excluded from the calculation. For the six months ended June 30, 2013, potentially issuable shares, including options and warrants to purchase 14,113,003 shares of the Company’s common stock and notes payable convertible to 19,603,263 shares of the Company’s common stock, have been excluded from the calculation.
Subsequent Events, Policy [Policy Text Block]	'
	Subsequent Events
	The Company has evaluated all transactions occurring between the six months ended June 30, 2014, through the date of issuance of the financial statements for subsequent event disclosure consideration.
Use of Estimates, Policy [Policy Text Block]	'
	Critical Accounting Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Standards
	In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders’ equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company evaluated and adopted ASU 2014-10 for the reporting period ended June 30, 2014.
Beneficial Conversion Feature [Member]	'
Accounting Policies, by Policy (Policies) [Line Items]	'
Derivatives, Policy [Policy Text Block]	'
	Beneficial Conversion Feature
	From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital.  The debt discount is amortized to interest expense over the life of the note using the effective interest method.

Note_1_Basis_of_Presentation_D1

Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassification (Tables)	6 Months Ended
	Jun. 30, 2014
Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassification (Tables) [Line Items]	'
Property, Plant and Equipment [Table Text Block]	'
		June 30,			December 31,
		2014			2013
	Equipment	$	353,235		$	353,235
	Leasehold improvement		44,000			44,000
	Furniture		49,147			49,147
			446,382			446,382
	Less accumulated depreciation		(218,326	)		(176,193	)
		$	228,056		$	270,189
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
		Level 1			Level 2			Level 3		Total
	Payable for indemnification	$	—		$	1,376,084		$	—	$	1,376,084
	Derivative liability	$	—		$	—		$	483,535	$	483,535
		Level 1			Level 2			Level 3		Total
	Payable for indemnification	$	—		$	1,376,084		$	—	$	1,376,084
	Derivative liability	$	—		$	—		$	658,453	$	658,453
Estimated Useful Life [Member]	'
Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassification (Tables) [Line Items]	'
Property, Plant and Equipment [Table Text Block]	'
	Asset Category	Useful Lives
	Machinery and equipment (years)	5
	Furniture and fixtures (years)	7
	Leasehold improvements	Shorter of leasehold improvement life or remaining term of lease

Note_3_Property_And_Equipment_

Note 3 - Property And Equipment (Tables)	6 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
		June 30,			December 31,
		2014			2013
	Equipment	$	353,235		$	353,235
	Leasehold improvement		44,000			44,000
	Furniture		49,147			49,147
			446,382			446,382
	Less accumulated depreciation		(218,326	)		(176,193	)
		$	228,056		$	270,189

Note_4_Intangibles_Tables

Note 4 - Intangibles (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
		June 30,			December 31,
		2014			2013
	Patent	$	192,543		$	184,906
	Less accumulated amortization		(53,309	)		(51,389	)
		$	139,234		$	133,517

Note_5_Accounts_Payable_and_Ac1

Note 5 - Accounts Payable and Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Payables and Accruals [Abstract]	'
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'
		30-Jun-14		31-Dec-13
	Accounts payable	$	600,953	$	565,127
	Accrued payroll liabilities and related penalties		596,475		607,134
	Accrued salary		671,280		418,440
	Accrued interest		217,803		158,869
	Other accruals		119,078		117,622
		$	2,205,589	$	1,867,192

Note_8_Convertible_Notes_Table

Note 8 - Convertible Notes (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Short-term Debt [Table Text Block]	'
		June 30,			December 31,
		2014			2013
	Convertible Promissory Note Payable to JMJ Financial, unsecured, one time interest charge of 8%, due on February 22, 2014 (in default)		191,663			191,663
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on May 19, 2014		-			35,000
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on July 23, 2014		-			42,500
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on September 12, 2014		-			47,500
	Convertible Promissory Note Payable to Carebourn Capital LP, unsecured, interest rate of 8% per annum, with payment due on June 30, 2014		-			32,500
	Convertible Promissory Note Payable to Carebourn Capital LP, unsecured, interest rate of 8% per annum, with payment due on July 29, 2014		-			10,000
	Convertible Promissory Note Payable to Carebourn Capital LP, unsecured, interest rate of 8% per annum, with payment due on August 29, 2014 (currently working with the creditor to convert this note into shares)		17,500			17,500
	Convertible Promissory Note Payable to TCA Global Credit Master Fund, LP, unsecured by all of the Company's assets, interest rate of 12% per annum, with payment due monthly until April 26, 2014 (in default)		189,844			189,844
	Convertible Promissory Note Payable issued in the course of a private placement to individual, unsecured, interest rate of 12% per annum, with payment due on April 9, 2014 or subsequently on demand by holder		-			140,862
	Convertible Promissory Note Payable issued in the course of a private placement to individual, unsecured, interest rate of 8% per annum, with payment due on September 3, 2014 (currently working with the creditor to convert this note into shares)		35,000			35,000
	Convertible Promissory Note Payable issued in the course of a private placement to individual, unsecured, interest rate of 8% per annum, with payment due on August 26, 2014 (currently working with the creditor to convert this note into shares)		75,000			75,000
	Convertible Promissory Note Payable to Carebourn Partners LLC, unsecured, interest rate of 8% per annum, with payment due on August 29, 2014 (currently working with the creditor to convert this note into shares)		15,000			-
	Convertible Promissory Note Payable to Booski Consulting LLC, unsecured, interest rate of 8% per annum, with payment due on December 17, 2014		5,000			-
	Convertible Promissory Note Payable to Linrick Industries LLC, unsecured, interest rate of 8% per annum, with payment due on December 17, 2014		5,000			-
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on December 4, 2014		53,000			-
	Convertible Promissory Note Payable to Carebourn, unsecured, interest rate of 12% per annum, with payment due on January 15, 2015		27,500			-
	Convertible Promissory Note Payable to KBM Worldwide, unsecured, interest rate of 8% per annum, with payment due on February 9, 2015		38,900			-
	Convertible Promissory Note Payable to Carebourn, unsecured, interest rate of 12% per annum, with payment due on January 15, 2015		52,500			-
			705,907			817,369
	Less: debt discount		(148,617	)		(247,661	)
		$	557,290		$	569,708

Note_9_Derivatives_Note_Conver1

Note 9 - Derivatives - Note Conversion Feature (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Text Block [Abstract]	'
Schedule of Derivative Instruments [Table Text Block]	'
	Fair value at December 31, 2013	$	658,453
	Decrease in value		(216,605	)
	Addition		339,506
	Reclassification from liability to equity as a result of note conversions		(297,819	)
	Fair value at June 30, 2014	$	483,535
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]	'
		June 30,			December 31,
		2014			2013
	Risk free interest rate		0.11%			0.13%
	Expected life (years)		0.01 to 0.61			0.07 to 0.7
	Dividend Yield		0%			0%
	Volatility		270% to 302%			256% to 394%
		Various issuance dates during the
		Six months ended			Year ended
		June 30,			December 31,
		2014			2013
	Risk free interest rate		0.09 to 0.13%			0.10 to 0.15%
	Expected life (years)		0.45 to 0.77			0.50 to 0.99
	Dividend Yield		0%			0%
	Volatility		251% to 280%			213% to 293%

Note_12_Stock_Options_and_Warr1

Note 12 - Stock Options and Warrants Outstanding (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Activity [Table Text Block]	'
		Number of			Weighted-		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
		Shares			average
		Under Option			Exercise
					Price
	Outstanding at December 31, 2013		5,500,000			0.12		0.36		-
	Granted		12,500,000			0.01		1.09
	Exercised		(1,000,000	)		0.02
	Forfeited or expired		(500,000	)		0.5
	Outstanding at June 30, 2014		16,500,000			0.03		0.96		-
		Number of			Weighted-		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
		Shares			average
		Under Option			Exercise
					Price
	Outstanding at December 31, 2013		6,249,008			0.17		0.34		-
	Granted		-			-		-
	Exercised		-			-
	Forfeited or expired		-
	Outstanding at June 30, 2014		6,249,008			0.17		0.32		-

Note_13_Related_Party_Transact1

Note 13 - Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions [Table Text Block]	'
		June 30,		December 31,
		2014		2013
	Stephen Wheet, Director of Sales	$	3,205	$	9,890
	Ron Wheet, Chief Executive Officer		9,579		-
	Vincent Olmo, Chief Operating Officer		1,443		942
		$	14,227	$	10,832

Note_1_Basis_of_Presentation_D2

Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassification (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014
			Stock Options and Warrants [Member]	Stock Options and Warrants [Member]	Convertible Debt Securities [Member]	Convertible Debt Securities [Member]	Minimum [Member]	Maximum [Member]
Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassification (Details) [Line Items]	'	'	'	'	'	'	'	'
Inventory Valuation Reserves (in Dollars)	$0	$0	'	'	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'	'	'	'	'17 years	'20 years
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	'	'	22,749,008	14,113,003	103,088,486	19,603,263	'	'

Note_1_Basis_of_Presentation_D3

Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassification (Details) - Estimated Useful Lives of Property Plant and Equipment	3 Months Ended
	Jun. 30, 2014
Machinery and Equipment [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and Equipment, Estimated Useful Lives	'5 years
Furniture and Fixtures [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and Equipment, Estimated Useful Lives	'7 years
Leasehold Improvements [Member]	'
Property, Plant and Equipment [Line Items]	'
Leasehold improvements	'Shorter of leasehold improvement life or remaining term of lease

Note_1_Basis_of_Presentation_D4

Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassification (Details) - Fair Value, Assets and Liabilities Measured on Recurring Basis (USD $)	Jun. 30, 2014	Dec. 31, 2013
Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassification (Details) - Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Cash and cash equivalents	$1,376,084	$1,376,084
Derivative liability	483,535	658,453
Fair Value, Inputs, Level 2 [Member]	'	'
Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassification (Details) - Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Cash and cash equivalents	1,376,084	1,376,084
Fair Value, Inputs, Level 3 [Member]	'	'
Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassification (Details) - Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Derivative liability	$483,535	$658,453

Note_2_Going_Concern_Details

Note 2 - Going Concern (Details) (USD $)	6 Months Ended		214 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Going Concern [Text Block] [Abstract]	'	'	'
Net Income (Loss) Attributable to Parent	($1,903,455)	($3,122,386)	($46,266,715)
Working Capital Defecit	'	'	$8,683,417

Note_3_Property_And_Equipment_1

Note 3 - Property And Equipment (Details) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'	'
Depreciation	$42,133	$43,234

Note_3_Property_And_Equipment_2

Note 3 - Property And Equipment (Details) - Summary of Property And Equipment (USD $)	Jun. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment	$446,382	$446,382
Less accumulated depreciation	-218,326	-176,193
	228,056	270,189
Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment	353,235	353,235
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment	44,000	44,000
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment	$49,147	$49,147

Note_4_Intangibles_Details

Note 4 - Intangibles (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Amortization of Intangible Assets	$1,920	$4,704

Note_4_Intangibles_Details_Sum

Note 4 - Intangibles (Details) - Summary of Intangible Assets (USD $)	Jun. 30, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Less accumulated amortization	($53,309)	($51,389)
	139,234	133,517
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Patent	$192,543	$184,906

Note_5_Accounts_Payable_and_Ac2

Note 5 - Accounts Payable and Accrued Liabilities (Details) (USD $)

3 Months Ended

6 Months Ended

1 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

26-May-14

Apr. 15, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2011

Jun. 30, 2014

Dec. 31, 2013

Yeso Med [Member]

Yeso Med [Member]

Yeso Med [Member]

Yeso Med [Member]

Yeso Med [Member]

Yeso Med [Member]

Yeso Med [Member]

Yeso Med [Member]

Yeso Med [Member]

Related to Minimum Purchase Requirement [Member]

Related to Minimum Purchase Requirement [Member]

Product Purchase [Member]

Product Purchase [Member]

Equipment Purchase [Member]

Equipment Purchase [Member]

Note 5 - Accounts Payable and Accrued Liabilities (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Payroll Taxes, Current

$596,475

'

$596,475

'

'

'

$607,134

'

'

'

'

'

'

'

'

'

Tax Lien, Amount

'

'

'

'

'

675,057

6,164

'

'

'

'

'

'

'

'

'

Change In Tax Lien, Amount

'

'

'

'

88,000

'

'

'

'

'

'

'

'

'

'

'

Long-term Purchase Commitment, Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

Long-term Purchase Commitment, Minimum Quantity Required

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

'

Purchase Commitment, Percentage of Supply Price

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

Accounts Payable, Current

'

'

'

'

'

'

'

3,689,969

2,749,075

208,501

208,501

289,519

289,519

'

4,187,989

3,247,095

Loss on Purchase Commitments

$480,914

$491,938

$940,894

$976,029

'

'

'

'

'

'

'

'

'

'

'

'

Note_5_Accounts_Payable_and_Ac3

Note 5 - Accounts Payable and Accrued Liabilities (Details) - Summary of Accounts Payable and Accrued Liabilities (USD $)	Jun. 30, 2014	Dec. 31, 2013
Summary of Accounts Payable and Accrued Liabilities [Abstract]	'	'
Accounts payable	$600,953	$565,127
Accrued payroll liabilities and related penalties	596,475	607,134
Accrued salary	671,280	418,440
Accrued interest	217,803	158,869
Other accruals	119,078	117,622
	$2,205,589	$1,867,192

Note_7_Payable_for_Indemnifica1

Note 7 - Payable for Indemnification (Details) (USD $)	0 Months Ended		6 Months Ended
	Mar. 15, 2012	Dec. 14, 2010	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Feb. 05, 2009	Mar. 11, 2005
Disclosure Text Block [Abstract]	'	'	'	'	'	'	'
	'	'	$1,376,084	'	$1,376,084	'	$1,088,067
Stock Issued During Period Shares For Special Account, Percentage of Daily Trading Volume	'	'	'	'	'	5.00%	'
Maximum Percentage of Special Account Shares Retained for Tax Liabilities	'	'	'	'	'	40.00%	'
Stock Issued During Period, Shares, for Indemnification (in Shares)	400,000	400,000	'	'	'	'	'
Stock Issued During Period, Value, for Indemnification	140,560	184,000	'	'	'	'	'
Net Loss on Stock Held in Special Account for Indemnification	'	'	$0	$19,535	'	'	'
Common Stock Held In Special Account For Indemnification Shares (in Shares)	'	'	301,463	'	'	'	'

Note_8_Convertible_Notes_Detai

Note 8 - Convertible Notes (Details) (USD $)

0 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

6 Months Ended

Jun. 11, 2013

9-May-13

Nov. 03, 2005

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2014

Oct. 09, 2013

Apr. 26, 2013

Feb. 22, 2011

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

5-May-14

Jun. 30, 2014

Feb. 28, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 19, 2014

15-May-14

Mar. 17, 2014

Jun. 30, 2014

Apr. 26, 2013

Dec. 31, 2013

9-May-13

Dec. 31, 2013

Apr. 26, 2013

Mar. 17, 2014

Jun. 30, 2014

Sep. 03, 2013

Oct. 09, 2013

Sep. 03, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Warrant 0.25 [Member]

Warrant .50 [Member]

September 3, 2013 Note [Member]

Convertible Debt [Member]

Stock Issued as Collateral [Member]

JMJ Note [Member]

JMJ Note [Member]

JMJ Note [Member]

JMJ Note [Member]

KBM Note [Member]

KBM Note [Member]

Asher Note 2014 [Member]

Asher Note 2014 [Member]

Asher Note 2013 [Member]

Carebourn Note 2014 [Member]

Carebourn Note 2014 [Member]

Carebourn Note 2014 [Member]

Carebourn Note 2014 [Member]

2013 TCA Purchase Agreement [Member]

2013 TCA Purchase Agreement [Member]

TCA Debentures [Member]

TCA Debentures [Member]

TCA Debentures [Member]

Individual Convertible Notes [Member]

Individual Convertible Notes [Member]

Individual Convertible Notes [Member]

Individual Convertible Notes 2013 [Member]

Individual Convertible Notes 2013 [Member]

Individual Convertible Notes 2013 [Member]

Individual Convertible Notes 2013 [Member]

Carebourn Note 2013 [Member]

TCA Global Credit Master Fund, LP [Member]

Individual Convertible Notes 2013 [Member]

Individual Convertible Notes 2013 [Member]

Individual Convertible Notes 2013 [Member]

Individual Convertible Notes 2013 [Member]

TCA Debentures [Member]

Note 8 - Convertible Notes (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Notes Payable

'

'

'

'

'

'

'

'

'

$1,050,000

$191,663

'

$191,663

'

'

'

'

'

'

'

'

'

$250,000

'

'

'

$250,000

'

'

$35,000

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

12.00%

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

12.00%

'

'

'

'

8.00%

'

8.00%

'

'

'

'

'

'

Percentage Of Common Stock Closing Price

'

'

'

'

'

'

'

'

'

70.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

$0.02

'

'

'

$0.00

'

$0.00

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

'

'

5,658

'

'

450,000

0

'

11,229

'

25,948

'

29,824

'

'

'

'

81,005

17,500

'

'

'

'

'

6,182

'

'

'

19,425

'

'

'

Interest Expense, Debt

'

'

'

'

'

'

'

'

'

'

11,229

39,671

'

'

'

'

'

'

'

'

'

'

'

11,781

'

'

'

'

'

'

'

2,837

17,740

'

'

'

Proceeds from Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

38,900

'

53,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Beneficial Conversion Feature

'

'

'

297,819

'

'

'

'

'

'

'

'

'

32,046

'

72,298

'

'

'

'

165,785

'

218,053

'

'

'

'

69,376

'

'

35,709

37,837

'

'

'

'

Interest on Convertible Debt, Net of Tax

'

'

'

-129,460

'

'

'

'

'

'

'

'

'

'

6,098

19,298

117,662

'

'

'

70,785

59,259

'

'

'

'

'

39,376

23,818

'

'

'

'

'

'

'

Convertible Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

38,900

'

53,000

'

'

'

'

112,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Amount

'

'

'

345,350

'

'

'

'

'

'

'

'

'

'

'

'

'

125,000

'

'

'

42,500

'

'

'

'

'

'

'

'

'

'

140,862

'

20,000

'

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,052,189

'

'

'

5,693,720

'

'

'

'

'

'

4,705,351

'

'

'

9,647,529

'

'

'

Proceeds from Convertible Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

52,500

27,500

15,000

'

'

'

'

'

'

15,000

'

'

140,862

'

'

'

'

'

Common Stock Purchase Agreement, Amount to be Purchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Inputs, Discount Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayments of Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

77,656

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument Convertible Price Percentage of Weighted Average Price of Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

85.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

250,000

'

'

'

'

'

'

'

9,375,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, New Issues

'

'

625,066

'

'

'

'

'

9,375

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

Facility Fee Satisfied

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

Leak Out Provision Threshold Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

Debt Issuance Cost

'

160,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unsold Shares (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

Increase (Decrease) in Other Accrued Liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60,000

'

'

'

'

'

'

'

'

'

'

Share Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.02

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

'

'

'

140,000

70,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

'

'

'

'

$0.25

$0.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and Rights Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,588

'

'

Percentage of Average Daily Volume

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

55.00%

'

'

'

'

'

'

'

'

Note_8_Convertible_Notes_Detai1

Note 8 - Convertible Notes (Details) - Notes Payable (USD $)	Jun. 30, 2014	Dec. 31, 2013
Short-term Debt [Line Items]	'	'
	$482,290	$494,708
Private Placement [Member] | Due September 3, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	35,000	35,000
Private Placement [Member] | Due August 26, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	75,000	75,000
First Issuance [Member] | Due August 29, 2014 [Member] | Carebourn Capital L.P. [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	17,500	17,500
Second Issuance [Member] | Due August 29, 2014 [Member] | Carebourn Capital L.P. [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	15,000	'
Including Related Parties [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	705,907	817,369
Less: debt discount	-148,617	-247,661
	557,290	569,708
Due February 22, 2014 [Member] | JMJ Financial Inc [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	191,663	191,663
Due May 19, 2014 [Member] | Asher Enterprises Inc [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	'	35,000
Due July 23, 2014 [Member] | Asher Enterprises Inc [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	'	42,500
Due September 12, 2014 [Member] | Asher Enterprises Inc [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	'	47,500
Due June 30, 2014 [Member] | Carebourn Capital L.P. [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	'	32,500
Due July 29, 2014 [Member] | Carebourn Capital L.P. [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	'	10,000
Due April 26, 2015 [Member] | TCA Global Credit Master Fund, LP [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	189,844	189,844
Due April 9, 2014 [Member] | Individual Counterparty [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	'	140,862
Due December 17, 2014 [Member] | Booski Consulting LLC [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	5,000	'
Due December 17, 2014 [Member] | Linrick Industries LLC [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	5,000	'
Due December 14, 2014 [Member] | Asher Enterprises Inc [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	53,000	'
Due February 15, 2015 [Member] | Carebourn Capital L.P. [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	27,500	'
Due February 20, 2015 [Member] | KBM Worldwide [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	38,900	'
Due March 27, 2015 [Member] | Carebourn Capital L.P. [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	$52,500	'

Note_8_Convertible_Notes_Detai2

Note 8 - Convertible Notes (Details) - Notes Payable (Parentheticals)	Jun. 30, 2014	Dec. 31, 2013
Private Placement [Member] | Due September 3, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	8.00%
Private Placement [Member] | Due August 26, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	8.00%
First Issuance [Member] | Due August 29, 2014 [Member] | Carebourn Capital L.P. [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	8.00%
Second Issuance [Member] | Due August 29, 2014 [Member] | Carebourn Capital L.P. [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	'
Due February 22, 2014 [Member] | JMJ Financial Inc [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	8.00%
Due May 19, 2014 [Member] | Asher Enterprises Inc [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	'	8.00%
Due July 23, 2014 [Member] | Asher Enterprises Inc [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	8.00%
Due September 12, 2014 [Member] | Asher Enterprises Inc [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	8.00%
Due June 30, 2014 [Member] | Carebourn Capital L.P. [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	8.00%
Due July 29, 2014 [Member] | Carebourn Capital L.P. [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	8.00%
Due April 26, 2015 [Member] | TCA Global Credit Master Fund, LP [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	12.00%	12.00%
Due April 9, 2014 [Member] | Individual Counterparty [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	12.00%	12.00%
Due December 17, 2014 [Member] | Booski Consulting LLC [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	'
Due December 17, 2014 [Member] | Linrick Industries LLC [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	'
Due December 14, 2014 [Member] | Asher Enterprises Inc [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	'
Due February 15, 2015 [Member] | Carebourn Capital L.P. [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	12.00%	'
Due February 20, 2015 [Member] | KBM Worldwide [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	'
Due March 27, 2015 [Member] | Carebourn Capital L.P. [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	12.00%	'

Note_9_Derivatives_Note_Conver2

Note 9 - Derivatives - Note Conversion Feature (Details) - Reconciliation of Derivative Liability (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Reconciliation of Derivative Liability [Abstract]	'	'
Fair value	$483,535	$658,453
Decrease in value	-216,605	'
Addition	339,506	'
Reclassification from liability to equity as a result of note conversions	($297,819)	'

Note_9_Derivatives_Note_Conver3

Note 9 - Derivatives - Note Conversion Feature (Details) - Fair Value Assumptions, Derivative Liability	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Risk free interest rate	0.11%	0.13%
Dividend Yield	0.00%	0.00%
Variant Issuance Dates [Member] | Minimum [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Risk free interest rate	0.09%	0.10%
Expected life (years)	'164 days	'6 months
Volatility	251.00%	213.00%
Variant Issuance Dates [Member] | Maximum [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Risk free interest rate	0.13%	0.15%
Expected life (years)	'281 days	'361 days
Volatility	280.00%	293.00%
Minimum [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Expected life (years)	'3 days	'25 days
Volatility	270.00%	256.00%
Maximum [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Expected life (years)	'222 days	'255 days
Volatility	302.00%	394.00%

Note_10_Commitments_and_Contin1

Note 10 - Commitments and Contingencies (Details) (USD $)

0 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

6 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

Jun. 11, 2013

Nov. 03, 2005

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jan. 30, 2012

Jan. 09, 2012

Dec. 31, 2013

Dec. 31, 2012

Jan. 02, 2013

Apr. 26, 2013

7-May-14

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Apr. 26, 2013

Oct. 21, 2011

Aug. 27, 2013

7-May-14

Jan. 02, 2013

Sep. 20, 2012

Mar. 15, 2012

Sep. 30, 2005

Sep. 30, 2005

Other Income [Member]

JMJ Financial Inc [Member]

JMJ Financial Inc [Member]

Former President and Director [Member]

Mold Production Payments [Member]

Mold Production Payments [Member]

Advisory Fee Requirement [Member]

Scenario, Plan [Member]

Per Payment for First Two Payments [Member]

Third Payment [Member]

Per Payment for Final Nine Payments [Member]

TCA Debentures [Member]

Globe Med Tech Inc. [Member]

Globe Med Tech Inc. [Member]

MIG and SPD [Member]

MIG and SPD [Member]

SEC [Member]

JMJ Financial Inc [Member]

Maxxon Inc [Member]

Globe Med Tech Inc. [Member]

MIG and SPD [Member]

Restricted Stock [Member]

MIG and SPD [Member]

MIG and SPD [Member]

MIG and SPD [Member]

MIG and SPD [Member]

MIG and SPD [Member]

MIG and SPD [Member]

Note 10 - Commitments and Contingencies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Obligation

$1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Price of Stock Percent

22.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for Fees

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible Asset, Patent, Ownership Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

50.00%

Joint Venture, Ownership Percentage

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, New Issues

'

625,066

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Litigation Settlement, Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

311,440

'

320,000

'

'

'

'

'

Litigation Settlement Shares (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

266,666

'

'

'

'

'

'

'

Shares Cancelled (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

266,666

'

'

'

'

'

'

Gain Contingency, Unrecorded Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

770,000

'

'

'

'

Proceeds from Legal Settlements

'

'

'

'

122,700

'

'

'

'

'

'

125,000

26,667

40,000

25,185

'

'

'

'

1,000,000

'

'

'

'

Property, Plant and Equipment, Gross

'

'

446,382

446,382

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Asset Impairment Charges

'

'

'

'

'

'

'

'

710,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Litigation Settlement Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

'

'

'

'

'

Loss Contingency Damages Sought Shares (in Shares)

'

'

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Requested Shares Of Common Stock Conversion (in Shares)

'

'

'

'

'

1,226,049

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,226,049

'

'

Loss Contingency, Damages Sought, Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

Securities Purchase Agreement Amount To Be Purchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

Convertible Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

'

'

'

'

'

'

'

'

Other Commitment

'

'

'

'

'

'

'

'

'

'

$100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_11_Preferred_Stock_and_Co1

Note 11 - Preferred Stock and Common Stock Transactions (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Note 11 - Preferred Stock and Common Stock Transactions (Details) [Line Items]	'	'
Preferred Stock, Shares Outstanding	1,000,000	1,000,000
Convertible Preferred Stock, Shares Issued upon Conversion	1	'
Preferred Stock, Voting Rights	'The holders of Preferred Stock are entitled to 125 votes for each share of common stock into which their Preferred Stock is then convertible (currently 1 share), voting together with our common stock as a single class. Cumulative voting is not permitted.	'
Common Stock, Voting Rights	'Upon conversion of a share of Preferred Stock, each share of common stock issued upon the conversion will be entitled to only one (1) vote per share.	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	1,000,000	'
Debt Conversion, Converted Instrument, Amount (in Dollars)	$345,350	'
Debt Instrument, Convertible, Beneficial Conversion Feature (in Dollars)	297,819	'
Series 2006 Preferred Stock [Member]	'	'
Note 11 - Preferred Stock and Common Stock Transactions (Details) [Line Items]	'	'
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)	$0.00	'
Chief Executive Officer [Member] | Series 2006 Preferred Stock [Member]	'	'
Note 11 - Preferred Stock and Common Stock Transactions (Details) [Line Items]	'	'
Preferred Stock, Shares Outstanding	'	1,000,000
Series 2006 Preferred Stock [Member]	'	'
Note 11 - Preferred Stock and Common Stock Transactions (Details) [Line Items]	'	'
Preferred Stock, Shares Outstanding	1,000,000	'
Common Stock [Member]	'	'
Note 11 - Preferred Stock and Common Stock Transactions (Details) [Line Items]	'	'
Stock Issued During Period, Shares, Issued for Services	1,000,000	'
Stock Issued During Period, Value, Issued for Services (in Dollars)	36,000	'
Stock Issued During Period Shares Accounts Payable Settlement	1,288,250	'
Stock Issued During Period Value Accounts Payable Settlement (in Dollars)	33,265	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	1,000,000	'
Stock Issued During Period, Value, Stock Options Exercised (in Dollars)	$20,000	'
Converted into Shares [Member]	'	'
Note 11 - Preferred Stock and Common Stock Transactions (Details) [Line Items]	'	'
Debt Conversion, Converted Instrument, Shares Issued	40,099,419	'

Note_12_Stock_Options_and_Warr2

Note 12 - Stock Options and Warrants Outstanding (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Jul. 31, 2011
Note 12 - Stock Options and Warrants Outstanding (Details) [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	'	20,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	12,500,000	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$0.01	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$0.50	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$81,478	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	199.00%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	285.00%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	'
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number	6,249,008	'
Modification Expense	$11,716	'
Employee Stock Option [Member] | Minimum [Member]	'	'
Note 12 - Stock Options and Warrants Outstanding (Details) [Line Items]	'	'
Fair Value Inputs, Discount Rate	0.09%	'
Employee Stock Option [Member] | Maximum [Member]	'	'
Note 12 - Stock Options and Warrants Outstanding (Details) [Line Items]	'	'
Fair Value Inputs, Discount Rate	0.12%	'
Exercise Price A [Member]	'	'
Note 12 - Stock Options and Warrants Outstanding (Details) [Line Items]	'	'
Share-Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number	4,166,005	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.13	'
Exercise Price B [Member]	'	'
Note 12 - Stock Options and Warrants Outstanding (Details) [Line Items]	'	'
Share-Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number	2,083,003	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.25	'
Minimum [Member]	'	'
Note 12 - Stock Options and Warrants Outstanding (Details) [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	'3 days	'
Maximum [Member]	'	'
Note 12 - Stock Options and Warrants Outstanding (Details) [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	'1 year 32 days	'

Note_12_Stock_Options_and_Warr3

Note 12 - Stock Options and Warrants Outstanding (Details) - Stock Options and Warrants Outstanding Activities (USD $)	0 Months Ended	6 Months Ended
	Dec. 31, 2013	Jun. 30, 2014	Dec. 31, 2013
Note 12 - Stock Options and Warrants Outstanding (Details) - Stock Options and Warrants Outstanding Activities [Line Items]	'	'	'
Number of Shares Under Option	'	16,500,000	5,500,000
Weighted-average Exercise Price	'	$0.03	$0.12
Weighted Average Remaining Contractual Term (in years)	'131 days	'350 days	'
Number of Shares Under Option	'	12,500,000	'
Weighted-average Exercise Price	'	$0.01	'
Weighted Average Remaining Contractual Term (in years)	'	'1 year 32 days	'
Number of Shares Under Option	'	-1,000,000	'
Weighted-average Exercise Price	'	$0.02	'
Number of Shares Under Option	'	-500,000	'
	'	$0.50	'
Warrant [Member]	'	'	'
Note 12 - Stock Options and Warrants Outstanding (Details) - Stock Options and Warrants Outstanding Activities [Line Items]	'	'	'
Number of Shares Under Option	'	6,249,008	6,249,008
Weighted-average Exercise Price	'	$0.17	$0.17
Weighted Average Remaining Contractual Term (in years)	'124 days	'116 days	'

Note_13_Related_Party_Transact2

Note 13 - Related Party Transactions (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jul. 01, 2011	Sep. 01, 2009	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013
			Osprey South, LLC [Member]	Osprey South, LLC [Member]	Osprey South, LLC [Member]	Osprey South, LLC [Member]	Osprey South, LLC [Member]	Chief Operating Officer [Member]	Chief Operating Officer [Member]	Chief Operating Officer [Member]
			5 Year Lease Agreement [Member]	5 Year Lease Agreement [Member]				Convertible Debt Securities [Member]
Note 13 - Related Party Transactions (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Lease Agreement Monthly Payment	'	'	$10,000	$4,500	'	'	'	'	'	'
Operating Leases, Rent Expense	'	'	'	'	60,000	60,000	'	'	'	'
Accrued Rent	'	'	'	'	81,662	'	112,962	'	'	'
Due to Related Parties	14,227	10,832	'	'	'	'	'	75,000	1,443	942
Interest Payable, Current	'	'	'	'	'	'	'	$11,613	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	'	'	'	'	'	8.00%	'	'

Note_13_Related_Party_Transact3

Note 13 - Related Party Transactions (Details) - Amounts Owed by the Company to its Executive Officers (USD $)	Jun. 30, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]	'	'
Executive officers	$14,227	$10,832
Director of Sales [Member]	'	'
Related Party Transaction [Line Items]	'	'
Executive officers	3,205	9,890
Chief Executive Officer [Member]	'	'
Related Party Transaction [Line Items]	'	'
Executive officers	9,579	'
Chief Operating Officer [Member]	'	'
Related Party Transaction [Line Items]	'	'
Executive officers	$1,443	$942

Note_14_Subsequent_Events_Deta

Note 14 - Subsequent Events (Details) (Subsequent Event [Member], USD $)	0 Months Ended
	Jul. 29, 2014	Jul. 29, 2014
Note 14 - Subsequent Events (Details) [Line Items]	'	'
Proceeds from Convertible Debt	$30,500	'
Debt Instrument, Covenant, Percentage Multiplied by Average of Lowest Three Trading Prices	'	53.00%
Fixed Conversion Price if Greater than 53% Multiplied by Lowest Three Trading Prices [Member]	'	'
Note 14 - Subsequent Events (Details) [Line Items]	'	'
Debt Instrument, Convertible, Conversion Price	$0.00	0.00005